Photo of Christopher W. Ryan, MD

Christopher W. Ryan MD

Dr. Ryan is a clinical researcher whose work focuses on testing new agents for renal carcinoma and sarcomas. He is particularly interested in clinical trial design and novel endpoints. He is currently studying the utility of dynamic contrast enhanced MRI data as a biomarker for activity of novel agents in the treatment of soft tissue sarcomas. His clinical practice is centered around an active trial portfolio.

  • Residency:

    • Internal medicine, University of Chicago, 1997
  • Fellowship:

    • Hematology/oncology, University of Chicago, 2000
  • Certifications:

    • American Board of Internal Medicine (medical oncology), 2000

Memberships and associations

  • American Society of Clinical Oncology


  • "Epirubicin and Ifosfamide with Preoperative Radiation for High-Risk Soft Tissue Sarcomas." Annals of Surgical Oncology  In: , Vol. 25, No. 4, 01.04.2018, p. 920-927.
  • "Adjuvant Vascular Endothelial Growth Factor–targeted Therapy in Renal Cell Carcinoma : A Systematic Review and Pooled Analysis." European Urology  In: , 01.01.2018.
  • "Mechanisms and funding opportunities in genitourinary cancer clinical research." Urologic Oncology: Seminars and Original Investigations  In: , 01.01.2018.
  • "ASO Author Reflections : Chemoradiation for High-Risk Soft Tissue Sarcomas." Annals of surgical oncology  In: , 01.01.2018.
  • "Correlation of Long-term Results of Imatinib in Advanced Gastrointestinal Stromal Tumors With Next-Generation Sequencing Results : Analysis of Phase 3 SWOG Intergroup Trial S0033." JAMA oncology  In: , Vol. 3, No. 7, 01.07.2017, p. 944-952.
  • "Dosing strategies and optimization of targeted therapy in advanced renal cell carcinoma." Journal of Oncology Pharmacy Practice  In: , Vol. 23, No. 1, 01.01.2017, p. 43-55.
  • "Doxorubicin plus evofosfamide versus doxorubicin alone in locally advanced, unresectable or metastatic soft-tissue sarcoma (TH CR-406/SARC021) : An international, multicentre, open-label, randomised phase 3 trial." The Lancet Oncology  In: , 2017.
  • "PICASSO III : A phase III, placebo-controlled study of doxorubicin with or without palifosfamide in patients with metastatic soft tissue sarcoma." Journal of Clinical Oncology  In: , Vol. 34, No. 32, 10.11.2016, p. 3898-3905.
  • "Everolimus versus sunitinib for patients with metastatic non-clear cell renal cell carcinoma (ASPEN) : A multicentre, open-label, randomised phase 2 trial." The Lancet Oncology  In: , Vol. 17, No. 3, 01.03.2016, p. 378-388.
  • "Metastatic renal cell carcinoma without evidence of a renal primary." International Urology and Nephrology  In: , Vol. 48, No. 1, 01.01.2016, p. 73-77.
  • "Neoadjuvant dasatinib for muscle-invasive bladder cancer with tissue analysis of biologic activity." Urologic Oncology: Seminars and Original Investigations  In: , Vol. 34, No. 1, 01.01.2016.
  • "Resistance exercise reduces body fat and insulin during androgen-deprivation therapy for prostate cancer." Oncology Nursing Forum  In: , Vol. 42, No. 4, 01.07.2015, p. 348-356.
  • "Preoperative Therapy for Extremity Soft Tissue Sarcomas." Current Treatment Options in Oncology  In: , Vol. 16, No. 6, 16.06.2015.
  • "A phase i study of everolimus and docetaxel in patients with castration-resistant prostate cancer." Clinical Genitourinary Cancer  In: , Vol. 13, No. 2, 01.04.2015, p. 113-123.
  • "A phase II study of sulforaphane-rich broccoli sprout extracts in men with recurrent prostate cancer." Investigational New Drugs  In: , Vol. 33, No. 2, 01.04.2015, p. 480-489.
  • "Resistance training reduces disability in prostate cancer survivors on androgen deprivation therapy : Evidence from a randomized controlled trial." Archives of Physical Medicine and Rehabilitation  In: , Vol. 96, No. 1, 01.01.2015, p. 7-14.
  • "Effect of dutasteride in men receiving intermittent androgen ablation therapy : The AVIAS trial." Journal of the Canadian Urological Association  In: , Vol. 8, No. 11-12, 01.11.2014, p. e789-e794.
  • "Skeletal response to resistance and impact training in prostate cancer survivors." Medicine and Science in Sports and Exercise  In: , Vol. 46, No. 8, 2014, p. 1482-1488.
  • "Phase i trial of preoperative chemoradiation plus sorafenib for high-risk extremity soft tissue sarcomas with dynamic contrast-enhanced MRI correlates." Clinical Cancer Research  In: , Vol. 19, No. 24, 15.12.2013, p. 6902-6911.
  • "A phase II study of tasisulam sodium (LY573636 sodium) as second-line or third-line treatment for patients with unresectable or metastatic soft tissue sarcoma." Investigational New Drugs  In: , Vol. 31, No. 1, 02.2013, p. 145-151.
  • "Overcoming autopsy barriers in pediatric cancer research." Pediatric Blood and Cancer  In: , Vol. 60, No. 2, 02.2013, p. 204-209.
  • "A molecular case report : Functional assay of tyrosine kinase inhibitors in cells from a patient's primary renal cell carcinoma." Cancer Biology and Therapy  In: , Vol. 14, No. 2, 02.2013, p. 95-99.
  • "MDM2 amplification and PI3KCA mutation in a case of sclerosing rhabdomyosarcoma." Sarcoma  In: , Vol. 2013, 520858, 2013.
  • "The past, present, and future of cytotoxic chemotherapy and pathway-directed targeted agents for soft tissue sarcoma." American Society of Clinical Oncology educational book / ASCO. American Society of Clinical Oncology. Meeting  In: , 2013.
  • "Promise and pitfalls of quantitative imaging in oncology clinical trials." Magnetic Resonance Imaging  In: , Vol. 30, No. 9, 11.2012, p. 1301-1312.
  • "Double-blind, randomized trial of docetaxel plus vandetanib versus docetaxel plus placebo in platinum-pretreated metastatic urothelial cancer." Journal of Clinical Oncology  In: , Vol. 30, No. 5, 10.02.2012, p. 507-512.
  • "Phase 2 Southwest Oncology Group-directed intergroup trial (S0505) of sorafenib in advanced soft tissue sarcomas." Cancer  In: , Vol. 118, No. 3, 01.02.2012, p. 770-776.
  • "Adjuvant systemic therapy for renal cell carcinoma."   Kidney Cancer: Principles and Practice. Springer Berlin Heidelberg, 2012. p. 172-186.
  • "A phase II study of everolimus in combination with imatinib for previously treated advanced renal carcinoma." Investigational New Drugs  In: , Vol. 29, No. 2, 04.2011, p. 374-379.
  • "Safety and efficacy of sorafenib in elderly patients treated in the North American advanced renal cell carcinoma sorafenib expanded access program." Oncology  In: , Vol. 78, No. 5-6, 09.2010, p. 340-347.

Additional information

Edit profile